Background: Mesenchymal stem cells (MSCs) display a therapeutic plasticity because of their ability to modulate immunity, foster tissue repair, and differentiate into mesodermal cells. IFN-g has been described to differently affect human mesenchymal stem cell (hMSC) and mouse mesenchymal stem cell (mMSC) immunomodulation and differentiation, depending on the inflammatory milieu. Objective: We aimed at dissecting the relevant intracellular pathways through which IFN-g affects MSC plasticity and the consequence of their manipulation on MSC functions. Methods: Modification of relevant IFN-g-dependent pathways in mMSCs was carried out in vitro through gene silencing or chemical inhibition of key components. Functional outcomes were assessed by means of Western blotting, real-time PCR, differentiation, and proliferation assays on MSCs. The effect on T cells was addressed by T-cell proliferation assays; the effect of mammalian target of rapamycin (mTOR) manipulation in MSCs was studied in vivo in a mouse model of delayed-type hypersensitivity assay. To address whether similar mechanisms are involved also in hMSCs on IFN-g stimulation, the effect of chemical inhibition on the same intracellular pathways was assessed by means of Western blotting, and the final outcome on immunomodulatory properties was evaluated based on realtime PCR and T-cell proliferation.
Results: We revealed that in mMSCs IFN-g-induced immunoregulation is mediated by early phosphorylation of signal transducer and activator of transcription (STAT) 1 and STAT3, which is significantly enhanced by an extracellular signal-regulated kinase 1/2-dependent mTOR inhibition, thereby promoting pSTAT1 nuclear translocation. Accordingly, after intracellular mTOR inhibition, MSCs augmented their ability to inhibit T-cell proliferation and control delayed-type hypersensitivity in vivo. Similarly, on mTOR blockade, hMSCs also enhanced their immunoregulatory features. A sustained exposure to IFN-g led to inhibition of STAT3 activity, which in mMSCs resulted in an impaired proliferation and differentiation. Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that can give rise to tissues of the mesodermal lineage in vitro and in vivo.
1 Although interest in MSCs was originally raised by their potential capacity to differentiate into different cell lineages, studies showing their immunologic properties have led to a revised concept, envisioning their use for immunomodulatory purposes 2 and consequent clinical translation in patients with many immune-mediated diseases. 3 MSCs mainly exert a regulatory effect on immune cells through release of soluble factors 4, 5 ; on the other hand, cytokines released by immune cells strongly influence MSC activity. In particular, IFN-g has been described to significantly affect human mesenchymal stem cell (hMSC) and mouse mesenchymal stem cell (mMSC) functions. Several studies showed that low concentrations of IFN-g induced the expression of MHC class II machinery in MSCs, promoting their proinflammatory function as antigenpresenting cells, [6] [7] [8] whereas the more extensively investigated anti-inflammatory function of MSCs is promoted by higher concentrations of IFN-g. 5, 9 IFN-g also affects differentiation and self-renewal, although controversial results have been reported. [10] [11] [12] Exposure to IFN-g was shown to induce the expression of factors, such as the inducible isoform of nitric oxide synthase 5 and indoleamine 2,3-dioxygenase, 10 and to affect the activation of intracellular signaling pathways, such as nuclear factor kB 13, 14 and Runt-related transcription factor 2 pathways, which mediate differentiation and immunomodulation exerted by MSCs. However, the mechanism of action and relevant pathways through which IFN-g affects MSC plasticity are poorly understood.
The major event on binding of IFN-g to its receptor is the phosphorylation and nuclear translocation of signal transducer and activator of transcription (STAT) 1, which drives the expression of target genes, most of which are involved in cell proliferation, antiviral responses, and immunomodulation. 15 Although STAT1 is the predominant transcription factor that mediates the biological effect of IFN-g both in human subjects and mice, STAT3, 16 phosphatidylinositol 3-kinase and its effector kinase AKT, and mitogen-activated protein kinase (extracellular signal-regulated kinase [ERK]) can be affected by IFN-g in a variety of cells. 17 The mammalian target of rapamycin (mTOR), a serine/ threonine kinase activated by AKT, controls cell proliferation and metabolism in response to a diverse range of extracellular stimuli, such as the availability of nutrients, growth factors, and stress. 18, 19 A growing body of evidence suggests that mTOR regulates functional outcome in a wide range of immune cells, including T cells, B cells, dendritic cells, macrophages, neutrophils, mast cells, and natural killer cells. 20 These pathways have been extensively studied in embryonic stem cells as molecular mechanisms driving self-renewal and pluripotency. 21 In particular, STAT3 plays a pivotal role in the regulation of stem cell self-renewal and differentiation. 22, 23 Here we dissected the intracellular pathways mediating the effect of IFN-g on MSC proliferation, differentiation, and ability to inhibit T-cell responses. In detail, we demonstrated that IFN-g promotes the immunomodulatory function of hMSCs and mMSCs by temporally activating both STAT1 and STAT3 and by reducing mTOR activity. In mice the inhibition of mTOR signaling by IFN-g occurs through an ERK1/2-dependent mechanism, promoting pSTAT1 nuclear translocation and enhancing the expression of immunomodulatory factors. After intracellular mTOR inhibition, both hMSCs and mMSCs significantly augmented their ability to control T cell-mediated immune responses, demonstrating that pharmacologic or genetic manipulation of MSCs might further enhance their immunomodulatory functions in vivo, which could be translated in novel therapeutic approaches.
METHODS

MSC culture and treatments
hMSCs purchased from Merck-Millipore (Billerica, Mass) and mMSCs isolated from bone marrow and characterized as previously described 24 were cultured in Mesencult medium (StemCell Technologies, Vancouver, British Columbia, Canada). MSCs were treated with IFN-g (human or mouse, according to the source of MSCs; R&D Systems. Minneapolis, Minn) for 1 hour in serum-free RPMI (Gibco, Carlsbad, Calif). For real-time PCR analysis at 24 hours, MSCs were cultured for a further 24 hours in serum-free RPMI. 
Real-time PCR
Pathway inhibition by pharmacologic agents
In both hMSCs and mMSCs, STAT3 inhibition was obtained by mean of exposure to cucurbitacin I (CUC; 500 nmol/L; Sigma-Aldrich, St Louis, Mo) for 3 hours, and mTOR and ERK1/2 inhibition was obtained through exposure to RAPA (100 nmol/L; Sigma-Aldrich) or U0126 (20 mmol/L; Calbiochem, San Diego, Calif), respectively, for 1 hour. Incubation with inhibitors was performed in serum-free RPMI, and then MSCs were extensively washed to remove any contamination during subsequent coculture experiments. The inhibition of STAT3, S6, and ERK phosphorylation was evaluated by means of Western blotting by using phospho-specific antibodies (Cell Signaling Technology, Beverly, Mass).
Western blotting
Western blot analysis was performed, as previously described, 25 in lysates of hMSCs and mMSCs. The blots were probed with antibodies specific for STAT1, phosphorylated (p) STAT1 (Tyr701), STAT3, pSTAT3 (Tyr705), S6, and pS6 (all 1:1000 dilution and from Cell Signaling Technology) and ERK1/2 and pERK1/2 (1:500 dilution; Santa Cruz Biotechnology, Santa Cruz, Calif). The filters were also probed with an actin antibody (1:1000 from Santa Cruz Biotechnology) to normalize for the amount of loaded protein. Pictures shown are representative of 3 experiments showing similar data. Relative densitometric quantifications of the gels after normalization of each phosphorylated protein on its specific total form were shown.
Inhibition of T-cell proliferation by MSCs
After pathway inhibition, as described above, MSCs were extensively washed to completely remove inhibitors and traces of Lipofectamine and siRNA and then irradiated (5000 rad) to block their proliferation. mMSCs were added to 2 3 10 5 anti-CD3/CD28-activated spleen cells labeled with carboxyfluorescein succinimidyl ester (1 mmol/L) at a ratio of 1:40 or 1:400. hMSCs were added to human PBMCs, labeled with carboxyfluorescein succinimidyl ester (1 mmol/L), and activated with PHA (1 mg/mL) at a ratio of 1:10 or 1:100. After 72 hours, splenocytes (mouse) or PBMCs (human) were collected, and the mean fluorescence intensity of CD3 Confocal microscopy mMSCs were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton, and labeled with antibodies specific for mouse pSTAT1 (1:100 dilution from Cell Signaling Technology), followed by a secondary antibody conjugated with Alexa Fluor 594. Nuclei were stained with 49-6-diamidino-2-phenylindole dihydrochloride. The slides were analyzed with a Nikon A1 laser scanning confocal microscopy equipped with 405-and 561-nm filters. Quantification of colocalization was carried out by using the Pearson index (mean 6 SD), which refers to the spatial overlap of DAPI (blue) with Alexa Fluor 594 (red) fluorescence and was evaluated for at least 100 mMSCs for each condition.
Delayed-type hypersensitivity
Delayed-type hypersensitivity (DTH) response to the peptide 323-339 of ovalbumin (OVA 323-339 ; InvivoGen, San Diego, Calif) was estimated based on footpad swelling. Mice (5 for group) were sensitized by means of a subcutaneous injection of 100 mL of 1 mg/mL OVA 323-339 emulsified with complete Freund adjuvant at 2 sites on the abdomen. Seven days after the immunization, mice (n 5 5 per group) were injected intravenously either with naive mMSCs or mMSCs exposed to RAPA (after extensive washes to remove traces of RAPA) or with mMSC CTRL-KD or mMSC RHEB-KD (5 3 10 5 cells per mouse). Next, mice were challenged by injection of 10 mL of 1 mg/mL OVA 323-339 in incomplete Freund adjuvant into 1 rear footpad, whereas the other rear footpad received a comparable volume of PBS in incomplete Freund adjuvant as a control. Footpad swelling was measured with a dial caliper 24 hours after the challenge. The magnitude of the DTH response was determined as the difference in footpad thickness between OVA 323-339 and PBSinjected footpads (Dmm). Data are presented as means 6 SDs of 3 different experiments.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed (Decreto Legislativo 4 marzo 2014, no. 
Statistical analysis
Statistical differences were evaluated by using the Student t test for unpaired data (2-tailed).
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RESULTS
On IFN-g stimulation, immunomodulation and stemness are alternative biological functions of MSCs
Microarray analysis of the transcriptome of mMSCs exposed to soluble factors released by activated T cells in vitro showed that genes involved in the immune response were the most upregulated (P 5 5.7E-10), with a significant enrichment of the interferon pathway (P 5 3.9E-7; see Table E1 , A, in this article's Online Repository at www.jacionline.org), whereas most downregulated genes were involved in the cell cycle (P 5 2.6E-10), extracellular matrix receptor interaction (P 5 8.7E-7) and lipid biosynthesis (P 5 2.1E-7), as well as in the development of tissues (P 5 2.7E-10), including many genes involved in Wnt (P 5 3.8E-2) and TGF-b (P 5 4.2E-2; see Table E1 , B). These data suggested that the immunomodulatory function of mMSCs is concomitant with an impaired lipid metabolism, cell cycle, stemness, and differentiation. Among the upregulated immune factors, we demonstrated that IL-18 binding protein (IL-18BP), an immunoregulatory molecule previously shown to inhibit Tcell functions, 26 is expressed by mMSCs (see Fig E1, A, in this article's Online Repository at www.jacionline.org). Il18bp gene silencing in mMSCs (see Fig E1, B) remarkably impaired their ability to control IL-18-mediated IFN-g production by T cells (see Fig E1, C) . 27 Because interferon signaling was the most represented pathway in mMSCs on crosstalk with activated T cells, we confirmed that, among the cytokines produced by T cells, IFN-g (10 ng/mL) promoted mMSC immunomodulation (see Fig E2, A, in this article's Online Repository at www.jacionline.org) and concomitantly impaired mMSC differentiation and proliferation (see Fig E2, B and C) . This effect is strictly dose dependent because a low dose of IFN-g (0.1 ng/mL) did not affect inhibition of T-cell proliferation and, conversely, mildly enhanced their ability to proliferate and promoted differentiation into osteocytes (see Fig E2) . These findings strengthened further the idea that immunomodulatory features of MSCs are inversely connected to their ability to proliferate or differentiate.
IFN-g temporally affects the activity of STAT1, STAT3, and mTOR pathways in mMSCs Next, we sought to elucidate the molecular mechanisms through which IFN-g affects mMSC plasticity. We analyzed the activity of the STAT1 and STAT3 pathways, which are implicated in IFN-g signaling, at 2 time points arbitrarily representative of early (1 hour) or late (24 hours) cellular events. Exposure to IFNg for 1 hour strongly induced phosphorylation of both STAT1 and STAT3 (Fig 1, A and B) . Although STAT1 phosphorylation was maintained on prolonged IFN-g exposure, STAT3 was completely dephosphorylated after exposure for 24 hours (Fig 1, A-C) . To address the different roles of the 2 transcription factors, we efficiently knocked down STAT1 and STAT3 (see Fig E3, A, in this article's Online Repository at www.jacionline.org). After both STAT1-KD or STAT3-KD, mMSCs displayed a reduced ability to inhibit T-cell proliferation in vitro (Fig 1, D and E) . However, only selective KD of STAT1, but not STAT3, impaired the expression of key factors, such as Cd274, 28 Nos2, 5 and Il18bp, which are involved in MSC immunomodulation and are induced by IFN-g (Fig 1, F and G) , thus suggesting the involvement of other molecules in the immunoregulatory effect mediated by STAT3.
Exposure of mMSCs to CUC, a STAT3 inhibitor mimicking the dephosphorylating effect of prolonged IFN-g exposure on STAT3 (see Fig E3, B) , strongly impaired mMSC proliferation (see Fig  E4, A, in this article's Online Repository at www.jacionline.org) and abrogated their differentiation (see Fig E4, B) , suggesting that modulation of STAT3 activity by IFN-g affects multiple MSC functions concomitantly.
Because the mTOR signaling pathway senses and integrates environmental cues to regulate cell functions, we also analyzed the activity of mTOR on exposure to IFN-g. Analysis of phosphorylated pathway components by means of Western blotting revealed that priming with IFN-g induces a transient dephosphorylation of S6, a downstream translational target used as readout of mTOR activity, as depicted by the reduction of pS6 levels after 1 hour, which was restored after 24 hours (Fig 1, A-C) . These results demonstrated that IFN-g temporally orchestrates phosphorylation of the STAT1 and STAT3 pathways, which are involved on mMSC immunomodulation, self-renewal, and differentiation, and suggested a new role for mTOR on MSC plasticity.
mTOR inhibition enhances mMSC immunomodulation and impairs differentiation in vitro
Then we analyzed the role of mTOR on mMSC immunomodulation through gene silencing of Rheb kinase (see Fig E3, A) , a key regulator of mTOR signaling, 29 and pharmacologic inhibition with RAPA. In line with our findings that mTOR inhibition by RAPA significantly enhanced the induction of immunomodulatory genes by IFN-g (Fig 2, A) , we observed that mTOR blockade, either through RAPA or gene silencing, enhanced mMSC antiproliferative activity in vitro (Fig 2, B and C) . This was demonstrated by the ability of RAPA-exposed and RHEB-KD mMSCs to considerably inhibit T-cell proliferation, even at a dilution (1:400) with effector cells at which mMSCs or mMSC CTRL-KD did not do so anymore. Results at different concentrations between mMSCs and effector cells allow us to highlight that mTOR inhibition results in a significant enhancement of the inhibitory effect on T-cell proliferation that is not yet detectable at a 1:40 ratio but strikingly evident at 1:400. Further supporting the role of mTOR inhibition on mMSC immunomodulation, we observed that a low concentration of IFN-g, which did not enhance immunomodulation, did not affect mTOR (and STAT3) activity but only induced STAT1 phosphorylation (see Fig E5 in this article' s Online Repository at www.jacionline.org). We also observed that mTOR inhibition did not significantly reduce mMSC proliferation (see Fig E4, D) but abrogated mMSC differentiation to osteocytes (see Fig E4, E and F) .
Inhibition of the mTOR intracellular pathway improves the ability of mMSCs to control DTH in vivo
The results described above demonstrated that inhibition of the mTOR pathway enhanced mMSC immunomodulatory features in vitro. Thus we sought to evaluate whether mMSCs with enhanced immunomodulatory properties can be used in vivo to control DTH, a prototypical T cell-mediated reaction. Thus we intravenously injected OVA-primed mice with naive mMSCs, CTRL-KD mMSCs, and RAPA-exposed and RHEB-KD mMSCs, shortly before boosting mice with OVA in the footpad. We observed a significant reduction in DTH as measured by a decreased footpad thickness in mice treated with RAPAexposed and RHEB-KD mMSCs compared with mice treated or not with naive mMSCs or CTRL-KD mMSCs (Fig 3) . These results confirm that manipulation of mTOR can be used to enhance in vivo the immunoregulatory features of mMSCs.
IFN-g-dependent mTOR inhibition promoted the nuclear translocation of pSTAT1
To assess whether the reduced activity of mTOR and subsequent increased immunoregulatory activity was associated with the activation of STAT1, the key transcription factor previously demonstrated to be involved in the immunoregulatory properties of MSCs, we analyzed activation of STAT1 in mMSCs in which the mTOR pathway was inhibited by RAPA. First, we confirmed that IFN-g increased nuclear translocation of pSTAT1 (Fig 4, A and B). More importantly, mTOR inhibition by RAPA strongly enhanced the nuclear localization of pSTAT1 to a greater extent in the presence of IFN-g (Fig 4, A and B) . Altogether, these results point to a major role for mTOR in the control of STAT1-dependent immunomodulatory function of mMSCs.
Pharmacologic ERK1/2 inhibition reverted the effect of IFN-g on mTOR
Because the phosphorylation of S6 in acute leukemia cells 30 had been described as an ERK1/2-dependent mechanism, we evaluated the effect of the ERK1/2 inhibitor U0126 on mTOR activation (as measured based on S6 phosphorylation) in mMSCs treated or not with IFN-g.
We observed that ERK1/2 inhibition reduced the phosphorylation of S6 in mMSCs at steady state and reverted the inhibitory effect of IFN-g (Fig 4, C and D) . Further supporting the connection between ERK1/2 and mTOR activity, we observed that IFN-g transiently reduced ERK1/2 phosphorylation, which was partially   FIG 1. IFN-g-induced STAT1 and STAT3 activation promotes mMSC immunomodulation. A-C, Representative Western blot of mMSCs exposed to IFN-g (10 ng/mL; Fig 1, A) and relative densitometric quantification after 1 hour (Fig 1, B) and 24 hours (Fig 1, C) , respectively. D, Representative in vitro T-cell proliferation assay plot. E, Proliferating T cells in the presence or absence of CTRL-KD, STAT1-KD and STAT3-KD mMSCs. F-G, PCR analysis of the expression of Cd274, Nos2, and Il18bp in CTRL-KD, STAT1-KD and STAT3-KD mMSCs. restored after 24 hours (Fig 4, E and F) , concomitantly with S6 phosphorylation (Fig 1, A-C) . Because S6 inhibition by RAPA resulted in increased nuclear translocation of pSTAT1, we sought to confirm the effect of ERK1/2 inhibition on S6 phosphorylation by measuring nuclear levels of pSTAT1 in mMSCs treated with U0126 compared with those in untreated MSCs. We observed that U0126 significantly enhanced the nuclear translocation of pSTAT1 similar to what was observed after RAPA exposure (Fig 4, G and H) , whereas IFN-g exposure did not further increase nuclear translocation of pSTAT1 in mMSCs in which ERK1/2 was inhibited by U0126 (Fig 4, G and H) . These results suggest a key role for ERK1/2 in IFN-g-dependent mTOR inhibition.
IFN-g orchestrates STAT1, STAT3, and mTOR pathways in human MSCs
Based on findings observed in mMSCs, we sought to assess whether the same pathways were affected by IFN-g also in hMSCs. Western blot analysis revealed that IFN-g induced early phosphorylation of STAT1 (Fig 5, A and B) , which is completely abrogated after 24 hours of exposure to IFN-g (Fig 5, A-C) . Early phosphorylation of STAT3 is followed by dephosphorylation on prolonged exposure to IFN-g (Fig 5, A-C) . Phosphorylation of S6, which is the readout of mTOR activity, is early enhanced by IFN-g and then reduced on prolonged exposure (Fig 5, A-C) . Because it has been demonstrated recently that downregulation of STAT1 abrogates the immunosuppressive capacity of human MSCs, 30 we sought to focus on STAT3, the role of which in MSC-mediated immunoregulation has never been addressed. We observed that blockade of STAT3 phosphorylation with CUC resulted in impairment of the ability of hMSCs to inhibit T-cell proliferation (Fig 5, D and E) . In addition, we found that, similar to what was observed in mMSCs, RAPA, which efficiently blocks S6 phosphorylation (see Fig E3, C) , increased the expression of Cd274 and Il18bp (Fig 5, F) . RAPA also promoted the ability of MSCs to inhibit T-cell proliferation in vitro (Fig 5, G  and H) , as depicted by an evident effect observed, even at a dilution with effector cells (1:100), at which MSCs not exposed to RAPA were ineffective. These results confirm that STAT3 and mTOR are relevant pathways involved also in hMSC immunomodulation.
DISCUSSION
MSCs, on expansion in vitro, are endowed with a striking ability to display anti-inflammatory and immunomodulatory properties and protect tissues through the release of antiapoptotic, (Fig 4, A) , and U0126 mMSCs (Fig 4, G) . B and H, Quantification of the colocalization between the 2 fluorophores 49-6-diamidino-2-phenylindole dihydrochloride (blue) and Alexa Fluor 594 (red) by using the Pearson index. C and D, Representative Western blot of mMSCs and U0126 mMSCs primed or not with IFN-g (Fig 4, C) and its densitometric quantification after normalization of phosphorylated protein on its total form (Fig 4, D) . E, Western blot analysis conducted after 1 or 24 hours of incubation with IFN-g. F, Relative densitometric quantitation of pERK1/2 after normalization of phosphorylated protein on its total form. proangiogenic, and proregenerative factors. 2 Many of these features are likely to be constitutive, as demonstrated by the striking effect observed in patients with experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis in which administration of conditioned medium from unprimed human MSCs led to clinical amelioration, inhibition of the pathogenic immune response against myelin antigens, and remyelination. 4 These functions are significantly augmented by IFN-g and other inflammatory cytokines, such as TNF-a and IL-1b, 5, 9 and are in agreement with the successful use of MSCs in the treatment of diseases in animals 24 and human subjects 31 dominated by T H 1 inflammation. Here we confirmed that IFN-g produced by activated T cells is mandatory for licensing the immunomodulatory features of MSCs, 5 and this occurs through upregulation of immunoregulatory genes in parallel with downregulation of genes involved in differentiation, proliferation, and stemness. These results are confirmed by the demonstration that mMSCs exposed to high concentrations of IFN-g increased their inhibitory function on proliferating T cells but also significantly decreased their ability to differentiate and proliferate. Several factors have been reported to play some roles in the immunoregulation exerted by MSCs. Here, based on results from the microarray analysis, we identified an important role not yet reported for IL-18BP in the ability of mMSCs to impair IFN-g production by T cells, thus suggesting that IL-18BP contributes to mMSC capacity to regulate T-cell effector functions.
We demonstrated that the effect of high concentrations of IFNg on hMSC and mMSC function is associated not only with phosphorylation of STAT1 and STAT3 but also with reduction of mTOR activity. Exposure to IFN-g resulted in dephosphorylation of S6 and hence inhibition of the mTOR pathway both in hMSCs and mMSCs. However, although in mMSCs mTOR inhibition occurred early, as detected on exposure to IFN-g for 1 hour, in hMSCs dephosphorylation of S6 appeared after priming with Fig 5, A) and its relative densitometric quantification after 1 hour (Fig 5, B) and 24 hours (Fig 5, C) . D, In vitro T-cell proliferation assay in the presence of hMSCs and CUC hMSCs. E, Proliferating T cells in the presence of MSC and CUC MSCs. F, PCR analysis of the expression of Cd274 and Il18bp in hMSCs and RAPA hMSCs. G, In vitro Tcell proliferation assay in the presence of hMSCs and RAPA hMSCs. H, Proliferating T cells in the presence or absence of hMSCs and RAPA hMSCs.
IFN-g for 24 hours, thus exhibiting different kinetics. Use of rapamycin revealed a key role of mTOR in regulation of the expression of IFN-g-dependent immunomodulatory genes in hMSCs and mMSCs. Moreover, chemical or genetic inhibition of mTOR enhanced the ability of both human and mouse cells to control T-cell proliferation in vitro. It is of great relevance that, regardless of the different kinetics of S6 dephosphorylation, inhibition of mTOR activity resulted in improvement of immunomodulatory features in both hMSCs and mMSCs.
In mMSCs the reduction of mTOR activity is dependent on ERK1/2 phosphorylation because ERK1/2 inhibition by U0126 reduced the basal level of pS6 and reverted the IFN-g-induced inhibition of S6 phosphorylation.
At a molecular level, we also demonstrated that in mMSCs mTOR inhibition by rapamycin promoted the nuclear translocation of pSTAT1, which resulted in a significantly increased ability of mMSCs to suppress T cell-mediated inflammation in a DTH mouse model. Accordingly, ERK1/2 inhibition, which impairs the activity of mTOR, led to an increased content of nuclear pSTAT1 in mMSCs. A role for mTOR as a regulator of mammalian gene transcription has been proposed, reporting a physical association between mTOR and STAT1 in lung epithelial adenocarcinoma cells and demonstrating that inactivation of mTOR enhanced this association, increasing STAT1 nuclear content. 32 Whether this association occurs also in hMSCs has yet to be demonstrated because dephosphorylation of S6 was detected after 24 hours of IFN-g exposure, when STAT1 is no longer phosphorylated.
In line with the recent demonstration of a major role for STAT1 in the regulation of immune functions of human MSCs, 33 we demonstrated that inhibition of STAT1, the principal transducer of IFN-g signaling, significantly impaired the induction of immunomodulatory markers and, consequently, the ability of mMSC to inhibit T-cell proliferation. For the first time, we also showed that STAT3 inhibition negatively affects the immunomodulatory function of MSCs, both in mice and human subjects, even though it did not interfere with the expression of Il18bp, Nos2, and Cd274, thus suggesting the possible involvement of other molecules in such a function.
Based on our results, we propose a mechanism of action through which IFN-g affects MSC plasticity. On binding with its receptor, IFN-g induces phosphorylation of STAT1 and STAT3 and inhibition of mTOR activity. Inhibition of mTOR favors, at least in mMSCs, nuclear translocation of pSTAT1, resulting in an increase in MSC immunomodulatory function. In mice, on dephosphorylation induced early by IFN-g, mTOR activity is restored after 24 hours and could be responsible for the late dephosphorylation of STAT3, 34 which negatively affects MSC differentiation potential and self-renewal. In contrast, in human MSCs S6 dephosphorylation occurs only after prolonged exposure to IFN-g, thus suggesting different kinetics or molecular mechanisms involved in mTOR inhibition but still resulting in an enhanced immunomodulatory activity.
Overall, these results not only provide some new insights about the intracellular pathways affected by IFN-g, a key cytokine licensing MSC immunoregulatory features, but also demonstrate that pharmacologic or genetic manipulation of MSCs might further enhance these functions, which could be potentially translated in in vivo approaches for the treatment of immunemediated diseases.
